Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARQT NYSE:ATIP NASDAQ:DYN NASDAQ:SNDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$15.52+0.2%$14.91$8.03▼$17.75$1.86B1.841.76 million shs1.19 million shsATIPATI Physical Therapy$0.68$0.77$0.01▼$6.59$2.98M-0.159,934 shs10 shsDYNDyne Therapeutics$13.49-1.9%$10.45$6.36▼$46.26$1.92B1.083.13 million shs1.97 million shsSNDAShanda Interactive Entertainment$25.84+13.3%$0.00$19.34▼$32.90$479.80M1.8352,862 shs32,857 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics0.00%-2.88%+6.45%+18.56%+45.18%ATIPATI Physical Therapy0.00%0.00%0.00%-24.58%-88.42%DYNDyne Therapeutics0.00%+7.23%+36.95%+14.13%-70.03%SNDAShanda Interactive Entertainment0.00%-3.06%+5.90%+5.71%-6.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARQTArcutis Biotherapeutics2.3395 of 5 stars3.42.00.00.02.51.70.6ATIPATI Physical TherapyN/AN/AN/AN/AN/AN/AN/AN/ADYNDyne Therapeutics3.5126 of 5 stars4.51.00.00.03.54.20.0SNDAShanda Interactive Entertainment0.0964 of 5 stars1.01.00.00.00.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARQTArcutis Biotherapeutics 2.86Moderate Buy$19.8027.58% UpsideATIPATI Physical Therapy 0.00N/AN/AN/ADYNDyne Therapeutics 3.06Buy$34.07152.53% UpsideSNDAShanda Interactive Entertainment 2.00Hold$26.000.62% UpsideCurrent Analyst Ratings BreakdownLatest SNDA, ATIP, DYN, and ARQT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025DYNDyne TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy$31.00 ➝ $35.008/7/2025ARQTArcutis BiotherapeuticsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/7/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.008/6/2025DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$34.00 ➝ $13.007/31/2025DYNDyne TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$66.00 ➝ $36.007/29/2025DYNDyne TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$25.00 ➝ $23.007/29/2025DYNDyne TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$37.00 ➝ $31.007/29/2025DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $38.007/25/2025ARQTArcutis BiotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$18.007/15/2025DYNDyne TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.007/11/2025DYNDyne TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARQTArcutis Biotherapeutics$196.54M9.47N/AN/A$1.16 per share13.38ATIPATI Physical Therapy$741.86M0.00$3.55 per share0.19($23.96) per share-0.03DYNDyne TherapeuticsN/AN/AN/AN/A$4.02 per shareN/ASNDAShanda Interactive Entertainment$255.32M1.93N/AN/A($14.07) per share-1.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARQTArcutis Biotherapeutics-$140.04M-$0.75N/AN/AN/A-35.40%-62.62%-25.16%11/5/2025 (Estimated)ATIPATI Physical Therapy-$69.79M-$19.42N/A∞N/A-7.79%N/A-3.87%11/3/2025 (Estimated)DYNDyne Therapeutics-$317.42M-$3.86N/AN/AN/AN/A-64.12%-56.75%11/11/2025 (Estimated)SNDAShanda Interactive Entertainment-$21.11M-$1.85N/AN/AN/A-4.02%N/A-6.11%N/ALatest SNDA, ATIP, DYN, and ARQT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025ARQTArcutis Biotherapeutics-$0.18-$0.13+$0.05-$0.13$72.70 million$81.50 million7/28/2025Q2 2025DYNDyne Therapeutics-$0.99-$0.97+$0.02-$0.97N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/AATIPATI Physical TherapyN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/ASNDAShanda Interactive EntertainmentN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARQTArcutis Biotherapeutics0.773.203.04ATIPATI Physical TherapyN/A1.121.12DYNDyne Therapeutics0.1716.8316.83SNDAShanda Interactive Entertainment6.972.342.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARQTArcutis BiotherapeuticsN/AATIPATI Physical Therapy72.60%DYNDyne Therapeutics96.68%SNDAShanda Interactive Entertainment87.55%Insider OwnershipCompanyInsider OwnershipARQTArcutis Biotherapeutics9.40%ATIPATI Physical Therapy3.30%DYNDyne Therapeutics14.14%SNDAShanda Interactive Entertainment5.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARQTArcutis Biotherapeutics150119.90 million108.63 millionOptionableATIPATI Physical Therapy5,6004.41 million4.27 millionNo DataDYNDyne Therapeutics100142.26 million122.15 millionOptionableSNDAShanda Interactive Entertainment3,95519.07 million18.12 millionNot OptionableSNDA, ATIP, DYN, and ARQT HeadlinesRecent News About These CompaniesSonida Senior Living (SNDA) Reports Q2 Loss, Beats Revenue EstimatesAugust 11, 2025 | zacks.comSonida Senior Living, Inc. (SNDA) Q2 2025 Earnings Conference Call TranscriptAugust 11, 2025 | seekingalpha.comSonida Senior Living Celebrates Growth and Community in Greater Atlanta RegionJuly 30, 2025 | businesswire.comVista Building at The Wellington at North Bend Crossing Secures Ohio Licensure, Opening Doors for New Assisted Living and Memory Care ResidentsJuly 30, 2025 | businesswire.comSonida Senior Living, Inc. (SNDA) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comSonida Senior Living (SNDA) Reports Q1 Loss, Tops Revenue EstimatesMay 12, 2025 | zacks.comSonida Senior Living Announces First Quarter 2025 ResultsMay 12, 2025 | businesswire.comSonida Announces Participation in Upcoming ConferencesMay 8, 2025 | businesswire.comThe Wellington at North Bend Crossing Expands Assisted Living and Memory Care Services, Coming Summer 2025May 2, 2025 | businesswire.comSonida Senior Living, Inc. (SNDA) Q4 2024 Earnings Call TranscriptMarch 17, 2025 | seekingalpha.comSonida Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Conference CallMarch 3, 2025 | businesswire.comSonida to Participate in Citi's 30th Annual Global Property CEO ConferenceFebruary 17, 2025 | businesswire.comSonida Senior Living Advances Clinical Excellence with August HealthFebruary 6, 2025 | businesswire.comSonida Announces Latest Asset Acquisition and Closing of Fannie Mae Maturity ModificationsJanuary 6, 2025 | businesswire.comSonida Senior Living, Inc. (SNDA) Q3 2024 Earnings Call TranscriptNovember 15, 2024 | seekingalpha.comSonida Senior Living Announces Third Quarter 2024 ResultsNovember 13, 2024 | businesswire.comSonida Continues Executing on its Accretive Growth and Capital Allocation Strategy with $48 Million of InvestmentsNovember 5, 2024 | businesswire.comSunda Energy Share Chat (SNDA)November 4, 2024 | lse.co.ukInteractive Harry Potter art experience to open on Sentosa on Nov 22November 1, 2024 | straitstimes.comSSonida Announces Third Quarter 2024 Earnings Release Date and Conference CallOctober 29, 2024 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 2025Buy the Dip? These Earnings Misses Offer Long-Term UpsideBy Nathan Reiff | August 7, 2025Why Teradyne's 19% Rally Is Just Getting StartedBy Jeffrey Neal Johnson | August 3, 2025SNDA, ATIP, DYN, and ARQT Company DescriptionsArcutis Biotherapeutics NASDAQ:ARQT$15.52 +0.03 (+0.19%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$15.40 -0.13 (-0.81%) As of 08/29/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.ATI Physical Therapy NYSE:ATIP$0.68 0.00 (0.00%) As of 07/31/2025ATI Physical Therapy, Inc. operates as an outpatient physical therapy provider that specializes in outpatient rehabilitation and adjacent healthcare services in the United States. It offers a range of services to its patients, including physical therapy to treat spine, shoulder, knee, and neck injuries or pain; work injury rehabilitation services, work conditioning and work hardening; and hand therapy, aquatic therapy, functional capacity evaluation, sports medicine, and wellness programs. It also provides ATI worksite solutions comprising injury prevention programs, work-related injury assessment services, wellness offerings, and consultations for employers; proprietary electronic medical records (EMR) integration, caseload management, and continuing education in therapy treatments; and sports medicine, including on-site sports physical therapy, clinical evaluation and diagnosis, immediate and emergency care, nutrition programs, and concussion management services. The company offers outpatient physical therapy services under the ATI brand name. ATI Physical Therapy, Inc. was founded in 1996 and is based in Bolingbrook, Illinois.Dyne Therapeutics NASDAQ:DYN$13.49 -0.26 (-1.89%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$13.23 -0.26 (-1.93%) As of 08/29/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Shanda Interactive Entertainment NASDAQ:SNDAShanda Interactive Entertainment Limited (Shanda Interactive) is an interactive entertainment media company. The Company offers a range of entertainment content portfolio, including among other things, massively multiplayer online role-playing game (MMORPG), advanced casual games and browser-based games without user-end software through Shanda Games, online (Internet and wireless value added services (WVAS)) and offline literature publication through Cloudary Corporation, a social network game community, including among others, online chess and board games, e-sports game platform and table game platform through Shanda Casual Community, WVAS and music through Hurray and online video through Ku6. In February 2012, Shanda Interactive merged with Premium Lead Company Limited and New Era Investment Holding Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
